Metabolomic Profile of Aggressive Meningiomas by Using High-Resolution Magic Angle Spinning Nuclear Magnetic Resonance

• Published in: Journal of proteome research 2020-01, Vol.19 (1), p.292-299
• Main Authors: Bender, Laura, Somme, François, Ruhland, Elisa, Cicek, A. Ercüment, Bund, Caroline, Namer, Izzie Jacques
• Format: Article
• Language: English
• Subjects: Amino Acids - analysis; Amino Acids - metabolism; Biopsy; Brain Neoplasms - metabolism; Brain Neoplasms - surgery; Cancer; Cell Proliferation; Computer Science; Humans; Ki-67 Antigen - metabolism; Life Sciences; Magnetic Resonance Spectroscopy - methods; Medical Imaging; Meningioma - metabolism; Meningioma - pathology; Meningioma - surgery; Metabolomics - methods; Neurons and Cognition
• ISSN: 1535-3893; 1535-3907
• DOI: 10.1021/acs.jproteome.9b00521

Meningiomas are in most cases benign brain tumors. The WHO 2016 classification defines three grades of meningiomas. This classification had a prognosis value because grade III meningiomas have a worse prognosis value compared to grades I and II meningiomas. However, some benign or atypical meningiomas can have a clinical aggressive behavior. There are currently no reliable markers which allow distinguishing between the meningiomas with a good prognosis and those which may recur. High-resolution magic angle spinning (HRMAS) spectrometry is a noninvasive method able to determine the metabolite profile of a tissue sample. We retrospectively analyzed 62 meningioma samples by using HRMAS spectrometry (43 metabolites). We described a metabolic profile defined by a high concentration for acetate, threonine, N-acetyl-lysine, hydroxybutyrate, myoinositol, ascorbate, scylloinositol, and total choline and a low concentration for aspartate, glucose, isoleucine, valine, adenosine, arginine, and alanine. This metabolomic signature was associated with poor prognosis histological markers [Ki-67 ≥ 40%, high histological grade and negative progesterone receptor (PR) expression]. We also described a similar metabolomic spectrum between grade III and grade I meningiomas. Moreover, all grade I meningiomas with a low Ki-67 expression and a positive PR expression did not have the same metabolomic profile. Metabolomic analysis could be used to determine an aggressive meningioma in order to discuss a personalized treatment. Further studies are needed to confirm these results and to correlate this metabolic profile with survival data.